A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2

מצבים רפואיים

Atopic Dermatitis

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • Atd002 52021, Oceanside, California, United States

  • Atd002 52008, Santa Monica, California, United States

  • Atd002 52013, Boca Raton, Florida, United States

  • Atd002 52007, Miami, Florida, United States

  • Atd002 52003, Miami, Florida, United States

  • Atd002 52015, Savannah, Georgia, United States

  • Atd002 52017, Chicago, Illinois, United States

  • Atd002 52018, Wheaton, Illinois, United States

  • Atd002 52012, New Albany, Indiana, United States

  • Atd002 52014, Bowling Green, Kentucky, United States

  • Atd002 52001, Troy, Michigan, United States

  • Atd002 52009, Troy, Michigan, United States

  • Atd002 52010, Omaha, Nebraska, United States

  • Atd002 52022, New York, New York, United States

  • Atd002 52020, The Bronx, New York, United States

  • Atd002 52019, Philadelphia, Pennsylvania, United States

  • Atd002 52005, Dallas, Texas, United States

  • Atd002 52016, Frisco, Texas, United States

  • Atd002 52011, Frisco, Texas, United States

  • Atd002 52004, Sugar Land, Texas, United States

  • Atd002 41004, Lovech, Bulgaria

  • Atd002 41001, Pleven, Bulgaria

  • Atd002 41007, Plovdiv, Bulgaria

  • Atd002 41002, Sevlievo, Bulgaria

  • Atd002 41003, Sofia, Bulgaria

  • Atd002 41005, Sofia, Bulgaria

  • Atd002 41006, Sofia, Bulgaria

  • Atd002 51002, Edmonton, Canada

  • Atd002 51006, Hamilton, Canada

  • Atd002 51007, Toronto, Canada

  • Atd002 51003, Vancouver, Canada

  • Atd002 42002, Náchod, Czechia

  • Atd002 42001, Prague, Czechia

  • Atd002 42003, Prague, Czechia

  • Atd002 42004, Prague, Czechia

  • Atd002 42005, Prague, Czechia

  • Atd002 43001, Bad Bentheim, Germany

  • Atd002 43005, Dresden, Germany

  • Atd002 43002, Frankfurt, Germany

  • Atd002 43004, Leipzig, Germany

  • Atd002 43003, Lübeck, Germany

  • Atd002 43007, Mahlow, Germany

  • Atd002 44003, Budapest, Hungary

  • Atd002 44001, Debrecen, Hungary

  • Atd002 21001, Habikino, Japan

  • Atd002 21002, Nagasaki, Japan

  • Atd002 21007, Nagoya, Japan

  • Atd002 21005, Sakai, Japan

  • Atd002 21008, Sapporo, Japan

  • Atd002 21004, Tachikawa-shi, Japan

  • Atd002 21006, Yokohama, Japan

  • Atd002 45011, Chorzów, Poland

  • Atd002 45001, Katowice, Poland

  • Atd002 45003, Krakow, Poland

  • Atd002 45007, Krakow, Poland

  • Atd002 45010, Krakow, Poland

  • Atd002 45014, Krakow, Poland

  • Atd002 45004, Lodz, Poland

  • Atd002 45013, Lodz, Poland

  • Atd002 45005, Sosnowiec, Poland

  • Atd002 45009, Tarnów, Poland

  • Atd002 45002, Warsaw, Poland

  • Atd002 45006, Warsaw, Poland

  • Atd002 45008, Wroclaw, Poland

  • Atd002 46004, London, United Kingdom

  • Atd002 46007, London, United Kingdom

  • Atd002 46003, Salford, United Kingdom

  • Atd002 46006, Sheffield, United Kingdom

מובילי המחקר
  • UCB Cares

    Study Director

    001 844 599 22733